aTYR PHARMA INC
ATYRNasdaq
$0.51
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↓ -91.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$50.0M
Enterprise Value
-$16.5M
P/E
—
P/S
—
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
-118.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$70.0M
Free Cash Flow (TTM)
-$59.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-120.9%
ROIC
—
Debt / Equity
—
Net Cash
$66.5M
Return 1Y
-91.2%
Company profile
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.
- CEO
- Sanjay S. Shukla
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 53
- Headquarters
- California
- Website
- atyrpharma.com
Management & directors
- Broadfoot Jill MarieChief Financial Officer
- Krueger NancyGeneral Counsel
- Shukla SanjayPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
ATYR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.11↓ -35.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.5M | $0.00 | $10.4M | $353,000.00 | $235,000.00 | $190,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.9M | -$34.0M | -$46.4M | -$54.9M | -$67.9M | -$77.6M |
| Net income | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| Diluted EPS | -$1.77 | -$1.77 | -$1.60 | -$0.94 | -$0.86 | -$0.80 |
| Operating cash flow | -$15.3M | -$33.1M | -$41.9M | -$33.2M | -$69.1M | -$62.0M |
| Free cash flow | -$15.5M | -$33.3M | -$43.5M | -$37.4M | -$69.2M | -$62.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -152.2% | — | -446.8% | -15557.8% | -28899.6% | -40856.3% |
| Net margin | -155.2% | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $190,000.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.3M | -$18.1M | -$15.8M | -$15.8M | -$20.3M | -$26.7M | -$14.8M | -$11.4M |
| Net income | -$16.3M | -$17.3M | -$15.0M | -$14.9M | -$19.5M | -$25.7M | -$14.0M | -$10.8M |
| Diluted EPS | -$0.23 | -$0.23 | -$0.17 | -$0.17 | -$0.22 | -$0.26 | -$0.15 | -$0.11 |
| Operating cash flow | -$20.4M | -$13.2M | -$13.1M | -$15.4M | -$13.9M | -$20.5M | -$12.2M | -$12.5M |
| Free cash flow | -$20.5M | -$13.2M | -$13.2M | -$15.4M | -$13.9M | -$20.5M | -$12.2M | -$12.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -14076.3% | — | — |
| Net margin | — | — | — | — | — | -13549.5% | — | — |
Company news
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | Buy | 100,000 | $0.50 | $49,630.00 | filing |
| 2026-02-04 | Shukla Sanjay· President and CEO | Sale | 3,745 | $0.98 | $3,655.12 | filing |
| 2026-02-04 | Broadfoot Jill Marie· Chief Financial Officer | Sale | 1,558 | $0.98 | $1,520.61 | filing |
| 2026-02-04 | Krueger Nancy· General Counsel | Sale | 1,118 | $0.98 | $1,091.28 | filing |
| 2026-02-03 | Shukla Sanjay· President and CEO | Option exercise | 10,375 | — | — | filing |
| 2026-02-03 | Broadfoot Jill Marie· Chief Financial Officer | Option exercise | 3,750 | — | — | filing |
| 2026-02-03 | Krueger Nancy· General Counsel | Option exercise | 2,687 | — | — | filing |
| 2025-10-09 | SCHIMMEL PAUL | Buy | 317,999 | $0.94 | $299,364.26 | filing |
| 2025-10-08 | SCHIMMEL PAUL | Buy | 682,001 | $0.90 | $612,436.90 | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.